GBM

This Phase 3 trial compares the drug niraparib to the standard chemo temozolomide in 450 adults with newly diagnosed, aggressive glioblastoma that has a specific genetic marker (MGMT unmethylated). Participants take the assigned drug daily during radiation, then continue until th…

This early-phase study tests whether adding a drug called S-Gboxin to standard treatment can help people with glioblastoma, a fast-growing brain cancer. The drug works by cutting off the energy supply to cancer cells. Ten patients with recurrent or progressive disease will receiv…

This early-stage trial tests a new surgical approach for recurrent glioblastoma, an aggressive brain cancer. After standard tumor removal, surgeons place a piece of abdominal tissue (omentum) into the brain cavity to bypass the blood-brain barrier. The study involves 10 adults an…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This trial tests an implantable ultrasound device that temporarily opens the blood-brain barrier, allowing chemotherapy to reach brain tumors. It includes 57 adults with recurrent glioblastoma who have already tried 1-2 treatments. The goal is to find a safe dose and see if this …

This early-phase trial tests the drug niraparib (Zejula) in people with two types of brain cancer: newly diagnosed glioblastoma and recurrent glioma with specific genetic changes (IDH mutation and ATRX loss). The study first checks if the drug reaches the tumor tissue, then gives…

This early-phase trial is testing whether giving two immune-boosting drugs (nivolumab and ipilimumab) before surgery can help fight recurrent glioblastoma, a fast-growing brain cancer. About 63 adults whose tumor has returned after standard treatment will receive the drugs or a p…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This phase 2 trial tests a combination of the drug niraparib and a device that delivers electric fields (Tumor-Treating Fields) in 30 people with recurrent glioblastoma, an aggressive brain cancer. The goal is to see if the combo can control the tumor, shrink it, or keep it stabl…

This study tests a new imaging technique called Deuterium Metabolic Imaging (DMI) to see if it can predict how well glioblastoma patients respond to treatment. Ten participants will drink a special glucose tracer before MRI scans. The goal is to improve treatment decisions, but t…